Dr Steven Kao

Map

Selected grants

2018

  • Predicting responses to cancer immunotherapy; Fazekas de St Groth B, Kao S; Cancer Council New South Wales/Program Grant.

2015

  • Do changes to chemotherapy dose increase toxicity explain poorer survival outcomes in advanced cancer patients with Systemic inflammation; Charles (nee Slaviero) K, Pearson S, Pearson S, Martin J, Diakos C, Kao S; University of Sydney/Sydney Catalyst Pilot - Seed Funding Grant.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Linton, A., Cheng, Y., Griggs, K., Schedlich, L., Kirschner, M., Gattani, S., Srikaran, S., Kao, S., McCaughan, B., Klebe, S., van Zandwijk, N., Reid, G. (2018). An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 118(6), e13. [More Information]
  • Ahmadzada, T., Kao, S., Reid, G., Boyer, M., Mahar, A., Cooper, W. (2018). An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 7(6), E153. [More Information]
  • Ahmadzada, T., Reid, G., Kao, S. (2018). Biomarkers in malignant pleural mesothelioma: current status and future directions. Journal of Thoracic Disease, 10(Suppl 9), S1003-S1007. [More Information]
  • Levy, D., Dhillon, H., Lomax, A., Marthick, M., McNeil, C., Kao, S., Lacey, J. (2018). Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Supportive Care in Cancer. [More Information]
  • Malalasekera, M., Dhillon, H., Blinman, P., Kao, S., Vardy, J. (2018). Delays to diagnosis and treatment of lung cancer in Australia: healthcare professional perceptions of actual versus acceptable timeframes. Internal Medicine Journal, 48(9), 1063-1071. [More Information]
  • Malalasekera, M., Dhillon, H., Blinman, P., Kao, S., Vardy, J. (2018). Delays to diagnosis and treatment of lung cancer in Australia: healthcare professional perceptions of actual versus acceptable timeframes. Internal Medicine Journal, 48(9), 1063-1071. [More Information]
  • Zaheed, M., Bray, V., Itchins, M., Storer, P., Kao, S. (2018). Development of Complex Hepatic Cysts Is a Potential Side Effect of Crizotinib. Journal of Thoracic Oncology, 13(4), e62-e64. [More Information]
  • Prasanna, T., Beith, J., Kao, S., Boyer, M., McNeil, C. (2018). Dose modifications in adjuvant chemotherapy for solid organ malignancies: A systematic review of clinical trials. Asia-Pacific Journal of Clinical Oncology, 14(3), 125-133. [More Information]
  • Johnson, T., Schelch, K., Cheng, Y., Williams, M., Sarun, K., Kirschner, M., Kao, S., Linton, A., Klebe, S., McCaughan, B., van Zandwijk, N., Reid, G., et al (2018). Dysregulated expression of the microRNA miR-137 and its target YB-1 contribute to the invasive characteristics of malignant pleural mesothelioma. Journal of Thoracic Oncology, 13(2), 258-272. [More Information]
  • Malalasekera, M., Nahm, S., Blinman, P., Kao, S., Dhillon, H., Vardy, J. (2018). How long is too long? A scoping review of health system delays in lung cancer. European Respiratory Review, 27(149), 1-17. [More Information]
  • Barnet, M., Cooper, W., Boyer, M., Kao, S. (2018). Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. Journal of Clinical Medicine, 7(6), 151. [More Information]
  • Barnet, M., Zielinski, R., Warby, A., Lewis, C., Kao, S. (2018). Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma. Journal of Thoracic Oncology, 13(1), e1-e2. [More Information]
  • Liu, R., Sebaratnam, D., Jackett, L., Kao, S., Lowe, P. (2018). Subacute cutaneous lupus erythematosus induced by nivolumab. Australasian Journal of Dermatology, 59(2), e152-e154. [More Information]
  • Bui, K., Cooper, W., Kao, S., Boyer, M. (2018). Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. Journal of Clinical Medicine, 7(8), 1-18. [More Information]
  • Malalasekera, M., Blinman, P., Dhillon, H., Stefanic, N., Grimison, P., Jain, A., D'Souza, M., Kao, S., Vardy, J. (2018). Times to Diagnosis and Treatment of Lung Cancer in New South Wales, Australia: A Multicenter, Medicare Data Linkage Study. Journal of Oncology Practice, 14(10), e621-e630. [More Information]
  • Barnet, M., Blinman, P., Cooper, W., Boyer, M., Kao, S., Goodnow, C. (2018). Understanding Immune Tolerance of Cancer: Re-Purposing Insights from Fetal Allografts and Microbes. BioEssays, 40(8), 1-6. [More Information]
  • Ahn, M., Kim, D., Cho, B., Kim, S., Lee, J., Ahn, J., Kim, T., Lin, C., Kim, H., Kao, S., et al (2017). Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. The Lancet Respiratory Medicine, 5(11), 891-902. [More Information]
  • Barnet, M., O'Toole, S., Horvath, L., Selinger, C., Yu, B., Ng, C., Boyer, M., Cooper, W., Kao, S. (2017). EGFR�Co-Mutated Advanced NSCLC and Response to�EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 12(3), 585-590. [More Information]
  • Linton, A., Soeberg, M., Broome, R., Kao, S., van Zandwijk, N. (2017). Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes. Respirology, 22(5), 978-985. [More Information]
  • Lau, B., Kumar, S., Yan, T., Burn, J., Kennedy, C., McLean, J., Boyer, M., McCaughan, B., Kao, S. (2017). Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes. Lung Cancer, 111, 75-78. [More Information]
  • Kresoja-Rakic, J., Sulemani, M., Kirschner, M., Ronner, M., Reid, G., Kao, S., Schwaller, B., Weder, W., Stahel, R., Felley-Bosco, E. (2017). Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma. Frontiers in Genetics, 8(70), 1-12. [More Information]
  • van Zandwijk, N., Pavlakis, N., Kao, S., Linton, A., Boyer, M., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M., Bailey, D., Cooper, W., Kritharides, L., Reid, G., et al (2017). Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. The Lancet Oncology, 18(10), 1386-1396. [More Information]
  • Kao, S., Cheng, Y., Williams, M., Kirschner, M., Madore, J., Lum, T., Sarun, K., Linton, A., McCaughan, B., Klebe, S., van Zandwijk, N., Scolyer, R., Boyer, M., Cooper, W., Reid, G. (2017). Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 12(9), 1421-1433. [More Information]
  • Kao, S., Kirschner, M., Cooper, W., Tran, T., Burgers, S., Wright, C., Korse, T., van den Broek, D., Edelman, J., Vallely, M., McCaughan, B., Pavlakis, N., Clarke, S., van Zandwijk, N., Reid, G., et al (2016). A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. British Journal of Cancer, 114(5), 524-531. [More Information]
  • Hoda, M., Dong, Y., Rozsas, A., Klikovits, T., Laszlo, V., Ghanim, B., Stockhammer, P., Ozsvar, J., Jakopovic, M., Reid, G., van Zandwijk, N., et al (2016). Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. European Journal of Cancer, 63, 64-73. [More Information]
  • Reid, G., Kao, S., Pavlakis, N., Brahmbhatt, H., MacDiarmid, J., Clarke, S., Boyer, M., van Zandwijk, N. (2016). Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics, 8(8), 1079-1085. [More Information]
  • Malalasekera, M., Tan, C., Phan, V., Yip, P., Vardy, J., Clarke, S., Kao, S. (2016). Eastern Cooperative Oncology Group score: Agreement between non-small-cell lung cancer patients and their oncologists and clinical implications. Cancer Treatment Communications, 5, 17-21. [More Information]
  • Kao, S., Boyer, M. (2016). Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 34(27), 3233-3234. [More Information]
  • Lomax, A., Beith, J., Bhadri, V., Boyer, M., Grimison, P., Horvath, L., Kao, S., Tattersall, M., Thomas, D., McNeil, C. (2016). Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse. Internal Medicine Journal, 46(12), 1392-1398. [More Information]
  • Bremnes, R., Busund, L., Kilvaer, T., Andersen, S., Richardsen, E., Paulsen, E., Hald, S., Khanehkenari, M., Cooper, W., Kao, S., et al (2016). The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. Journal of Thoracic Oncology, 11(6), 789-800. [More Information]
  • Kao, S., Fulham, M., Wong, K., Cooper, W., Brahmbhatt, H., MacDiarmid, J., Pattison, S., Sagong, J., Huynh, Y., Leslie, F., Pavlakis, N., Clarke, S., Boyer, M., Reid, G., van Zandwijk, N. (2015). A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. American Journal of Respiratory and Critical Care Medicine, 191(12), 1467-1469. [More Information]
  • Kao, S., van Zandwijk, N., Clarke, S., Vardy, J., Lumba, S., Tognela, A., Ng, W. (2015). Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: An evidence-based benchmark for cancer care. Asia-Pacific Journal of Clinical Oncology, 11, 85-92. [More Information]
  • Kirschner, M., Emily, P., Hoda, M., Rozsas, A., Griggs, K., Cheng, Y., Edelman, J., Kao, S., Hyland, R., Dong, Y., Vallely, M., van Zandwijk, N., Reid, G., et al (2015). Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. British Journal of Cancer, 113(6), 963-969. [More Information]
  • Williams, M., Kirschner, M., Cheng, Y., Hanh, J., Weiss, J., Amaro-Mugridge, N., Wright, C., Linton, A., Kao, S., Edelman, J., Vallely, M., Cooper, W., van Zandwijk, N., Reid, G., et al (2015). miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget, 6(27), 23480-23495. [More Information]
  • Kirschner, M., Cheng, Y., Armstrong, N., Lin, R., Kao, S., Linton, A., Klebe, S., McCaughan, B., van Zandwijk, N., Reid, G. (2015). MiR-Score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Molecular Oncology, 9(3), 715-726. [More Information]
  • Cooper, W., Tran, T., Vilain, R., Madore, J., Selinger, C., Kohonen-Corish, M., Yip, P., Yu, B., O'Toole, S., McCaughan, B., Horvath, L., Kao, S., Boyer, M., Scolyer, R., et al (2015). PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, 89(2), 181-188. [More Information]
  • Linton, A., Cheng, Y., Griggs, K., Kirschner, M., Gattani, S., Srikaran, S., Kao, S., McCaughan, B., Klebe, S., van Zandwijk, N., Reid, G. (2014). An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 110(2), 510-519. [More Information]
  • Kao, S., van Zandwijk, N., Clarke, S. (2014). Comment on 'Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'. British Journal of Cancer, 111(12), 2376-2376. [More Information]
  • Linton, A., Pavlakis, N., O’Connell, R., Soeberg, M., Kao, S., Clarke, S., Vardy, J., van Zandwijk, N. (2014). Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. British Journal of Cancer, 111(9), 1860-1869. [More Information]
  • Henderson, D., Reid, G., Kao, S., Van Zandwijk, N., Klebe, S. (2013). Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. Journal of Clinical Pathology, 66(10), 854-861. [More Information]
  • Henderson, D., Reid, G., Kao, S., Van Zandwijk, N., Klebe, S. (2013). Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. Journal of Clinical Pathology, 66(10), 847-853. [More Information]
  • Kao, S., Lee, K., Klebe, S., Henderson, D., McCaughan, B., Vardy, J., Clarke, S., van Zandwijk, N. (2013). Excision Repair Cross Complementation Group 1 and Thymidylate Synthase Expression in Patients With Mesothelioma. Clinical Lung Cancer, 14(2), 164-171. [More Information]
  • Kao, S., Vardy, J., Harvie, R., Chatfield, M., van Zandwijk, N., Clarke, S., Pavlakis, N. (2013). Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Supportive Care in Cancer, 21(3), 697-705. [More Information]
  • Linton, A., Kao, S., Vardy, J., Clarke, S., van Zandwijk, N., Klebe, S. (2013). Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review. Asia-Pacific Journal of Clinical Oncology, 9(3), 273-279. [More Information]
  • Honeyball, F., Boyer, M., van Zandwijk, N., Kao, S. (2013). Malignant pleural mesothelioma. Cancer Forum, 37(2), 181-185.
  • Kao, S., Clarke, S., Vardy, J., Corte, P., Clarke, C., van Zandwijk, N. (2013). Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. Internal Medicine Journal, 43(4), 402-410. [More Information]
  • Kirschner, M., Edelman, J., Kao, S., Vallely, M., van Zandwijk, N., Reid, G. (2013). The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Frontiers in Genetics, 4, 1-13. [More Information]
  • Kao, S., van Zandwijk, N., Corte, P., Clarke, C., Clarke, S., Vardy, J. (2013). Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. Supportive Care in Cancer, 21(7), 1879-1884. [More Information]
  • Kao, S., Vardy, J., Chatfield, M., Corte, P., Pavlakis, N., Clarke, C., van Zandwijk, N., Clarke, S. (2013). Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data from Patients Seeking Compensation from the New South Wales Dust Diseases Board. Clinical Lung Cancer, 14(1), 70-77. [More Information]
  • Kao, S., Armstrong, N., Condon, B., Griggs, K., McCaughan, B., Maltby, S., Wilson, A., Henderson, D., Klebe, S. (2012). Aquaporin 1 is an Independent Prognostic Factor in Pleural Malignant Mesothelioma. Cancer, 118(11), 2952-2961. [More Information]
  • Kirschner, M., Cheng, Y., Badrian, B., Kao, S., Creaney, J., Edelman, J., Armstrong, N., Vallely, M., Musk, A., Robinson, B., McCaughan, B., van Zandwijk, N., Reid, G., et al (2012). Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 7(7), 1184-1191. [More Information]
  • Linton, A., van Zandwijk, N., Reid, G., Clarke, S., Cao, C., Kao, S. (2012). Inflammation in malignant mesothelioma - friend or foe? Annals of Cardiothoracic Surgery, 1(4), 516-522. [More Information]
  • van Zandwijk, N., Reid, G., Linton, A., Kao, S. (2012). Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools? Annals of Cardiothoracic Surgery, 1(4), 481-486. [More Information]
  • Clarey, J., Kao, S., Clarke, S., Vardy, J. (2012). The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials. Annals of Oncology, 23(5), 1229-1233. [More Information]
  • Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012). The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer, 75(2), 248-254. [More Information]
  • Kirschner, M., Kao, S., Edelman, J., Armstrong, N., Vallely, M., van Zandwijk, N., Reid, G. (2011). Haemolysis during Sample Preparation Alters microRNA Content of Plasma. PloS One, 6(9), 1-9. [More Information]
  • Kao, S., Klebe, S., Henderson, D., Reid, G., Chatfield, M., Armstrong, N., Yan, T., Vardy, J., Clarke, S., van Zandwijk, N., McCaughan, B. (2011). Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy. Journal of Thoracic Oncology, 6(11), 1923-1929. [More Information]
  • Kao, S., Reid, G., van Zandwijk, N., Henderson, D., Klebe, S. (2011). Molecular biomarkers in malignant mesothelioma: state of the art. Pathology, 43(3), 201-212. [More Information]
  • Kao, S., Hovey, E., Marx, G. (2011). Second-line therapy for castrate-resistant prostate cancer: A literature review. Asia-Pacific Journal of Clinical Oncology, 7, 212-223. [More Information]
  • Kao, S., Griggs, K., Lee, K., Armstrong, N., Clarke, S., Vardy, J., van Zandwijk, N., Burn, J., McCaughan, B., Henderson, D., et al (2011). Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology, 43(4), 313-317. [More Information]
  • Kao, S., Lee, K., Armstrong, N., Clarke, S., Vardy, J., van Zandwijk, N., Reid, G., Burn, J., McCaughan, B., Henderson, D., et al (2011). Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology, 43(2), 128-132. [More Information]

2018

  • Linton, A., Cheng, Y., Griggs, K., Schedlich, L., Kirschner, M., Gattani, S., Srikaran, S., Kao, S., McCaughan, B., Klebe, S., van Zandwijk, N., Reid, G. (2018). An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 118(6), e13. [More Information]
  • Ahmadzada, T., Kao, S., Reid, G., Boyer, M., Mahar, A., Cooper, W. (2018). An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 7(6), E153. [More Information]
  • Ahmadzada, T., Reid, G., Kao, S. (2018). Biomarkers in malignant pleural mesothelioma: current status and future directions. Journal of Thoracic Disease, 10(Suppl 9), S1003-S1007. [More Information]
  • Levy, D., Dhillon, H., Lomax, A., Marthick, M., McNeil, C., Kao, S., Lacey, J. (2018). Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Supportive Care in Cancer. [More Information]
  • Malalasekera, M., Dhillon, H., Blinman, P., Kao, S., Vardy, J. (2018). Delays to diagnosis and treatment of lung cancer in Australia: healthcare professional perceptions of actual versus acceptable timeframes. Internal Medicine Journal, 48(9), 1063-1071. [More Information]
  • Malalasekera, M., Dhillon, H., Blinman, P., Kao, S., Vardy, J. (2018). Delays to diagnosis and treatment of lung cancer in Australia: healthcare professional perceptions of actual versus acceptable timeframes. Internal Medicine Journal, 48(9), 1063-1071. [More Information]
  • Zaheed, M., Bray, V., Itchins, M., Storer, P., Kao, S. (2018). Development of Complex Hepatic Cysts Is a Potential Side Effect of Crizotinib. Journal of Thoracic Oncology, 13(4), e62-e64. [More Information]
  • Prasanna, T., Beith, J., Kao, S., Boyer, M., McNeil, C. (2018). Dose modifications in adjuvant chemotherapy for solid organ malignancies: A systematic review of clinical trials. Asia-Pacific Journal of Clinical Oncology, 14(3), 125-133. [More Information]
  • Johnson, T., Schelch, K., Cheng, Y., Williams, M., Sarun, K., Kirschner, M., Kao, S., Linton, A., Klebe, S., McCaughan, B., van Zandwijk, N., Reid, G., et al (2018). Dysregulated expression of the microRNA miR-137 and its target YB-1 contribute to the invasive characteristics of malignant pleural mesothelioma. Journal of Thoracic Oncology, 13(2), 258-272. [More Information]
  • Malalasekera, M., Nahm, S., Blinman, P., Kao, S., Dhillon, H., Vardy, J. (2018). How long is too long? A scoping review of health system delays in lung cancer. European Respiratory Review, 27(149), 1-17. [More Information]
  • Barnet, M., Cooper, W., Boyer, M., Kao, S. (2018). Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. Journal of Clinical Medicine, 7(6), 151. [More Information]
  • Barnet, M., Zielinski, R., Warby, A., Lewis, C., Kao, S. (2018). Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma. Journal of Thoracic Oncology, 13(1), e1-e2. [More Information]
  • Liu, R., Sebaratnam, D., Jackett, L., Kao, S., Lowe, P. (2018). Subacute cutaneous lupus erythematosus induced by nivolumab. Australasian Journal of Dermatology, 59(2), e152-e154. [More Information]
  • Bui, K., Cooper, W., Kao, S., Boyer, M. (2018). Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. Journal of Clinical Medicine, 7(8), 1-18. [More Information]
  • Malalasekera, M., Blinman, P., Dhillon, H., Stefanic, N., Grimison, P., Jain, A., D'Souza, M., Kao, S., Vardy, J. (2018). Times to Diagnosis and Treatment of Lung Cancer in New South Wales, Australia: A Multicenter, Medicare Data Linkage Study. Journal of Oncology Practice, 14(10), e621-e630. [More Information]
  • Barnet, M., Blinman, P., Cooper, W., Boyer, M., Kao, S., Goodnow, C. (2018). Understanding Immune Tolerance of Cancer: Re-Purposing Insights from Fetal Allografts and Microbes. BioEssays, 40(8), 1-6. [More Information]

2017

  • Ahn, M., Kim, D., Cho, B., Kim, S., Lee, J., Ahn, J., Kim, T., Lin, C., Kim, H., Kao, S., et al (2017). Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. The Lancet Respiratory Medicine, 5(11), 891-902. [More Information]
  • Barnet, M., O'Toole, S., Horvath, L., Selinger, C., Yu, B., Ng, C., Boyer, M., Cooper, W., Kao, S. (2017). EGFR�Co-Mutated Advanced NSCLC and Response to�EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 12(3), 585-590. [More Information]
  • Linton, A., Soeberg, M., Broome, R., Kao, S., van Zandwijk, N. (2017). Geographic and socioeconomic factors in patients with malignant pleural mesothelioma in New South Wales and their impact upon clinical outcomes. Respirology, 22(5), 978-985. [More Information]
  • Lau, B., Kumar, S., Yan, T., Burn, J., Kennedy, C., McLean, J., Boyer, M., McCaughan, B., Kao, S. (2017). Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes. Lung Cancer, 111, 75-78. [More Information]
  • Kresoja-Rakic, J., Sulemani, M., Kirschner, M., Ronner, M., Reid, G., Kao, S., Schwaller, B., Weder, W., Stahel, R., Felley-Bosco, E. (2017). Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma. Frontiers in Genetics, 8(70), 1-12. [More Information]
  • van Zandwijk, N., Pavlakis, N., Kao, S., Linton, A., Boyer, M., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M., Bailey, D., Cooper, W., Kritharides, L., Reid, G., et al (2017). Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. The Lancet Oncology, 18(10), 1386-1396. [More Information]
  • Kao, S., Cheng, Y., Williams, M., Kirschner, M., Madore, J., Lum, T., Sarun, K., Linton, A., McCaughan, B., Klebe, S., van Zandwijk, N., Scolyer, R., Boyer, M., Cooper, W., Reid, G. (2017). Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 12(9), 1421-1433. [More Information]

2016

  • Kao, S., Kirschner, M., Cooper, W., Tran, T., Burgers, S., Wright, C., Korse, T., van den Broek, D., Edelman, J., Vallely, M., McCaughan, B., Pavlakis, N., Clarke, S., van Zandwijk, N., Reid, G., et al (2016). A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. British Journal of Cancer, 114(5), 524-531. [More Information]
  • Hoda, M., Dong, Y., Rozsas, A., Klikovits, T., Laszlo, V., Ghanim, B., Stockhammer, P., Ozsvar, J., Jakopovic, M., Reid, G., van Zandwijk, N., et al (2016). Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. European Journal of Cancer, 63, 64-73. [More Information]
  • Reid, G., Kao, S., Pavlakis, N., Brahmbhatt, H., MacDiarmid, J., Clarke, S., Boyer, M., van Zandwijk, N. (2016). Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics, 8(8), 1079-1085. [More Information]
  • Malalasekera, M., Tan, C., Phan, V., Yip, P., Vardy, J., Clarke, S., Kao, S. (2016). Eastern Cooperative Oncology Group score: Agreement between non-small-cell lung cancer patients and their oncologists and clinical implications. Cancer Treatment Communications, 5, 17-21. [More Information]
  • Kao, S., Boyer, M. (2016). Evolving Landscape of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 34(27), 3233-3234. [More Information]
  • Lomax, A., Beith, J., Bhadri, V., Boyer, M., Grimison, P., Horvath, L., Kao, S., Tattersall, M., Thomas, D., McNeil, C. (2016). Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse. Internal Medicine Journal, 46(12), 1392-1398. [More Information]
  • Bremnes, R., Busund, L., Kilvaer, T., Andersen, S., Richardsen, E., Paulsen, E., Hald, S., Khanehkenari, M., Cooper, W., Kao, S., et al (2016). The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. Journal of Thoracic Oncology, 11(6), 789-800. [More Information]

2015

  • Kao, S., Fulham, M., Wong, K., Cooper, W., Brahmbhatt, H., MacDiarmid, J., Pattison, S., Sagong, J., Huynh, Y., Leslie, F., Pavlakis, N., Clarke, S., Boyer, M., Reid, G., van Zandwijk, N. (2015). A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. American Journal of Respiratory and Critical Care Medicine, 191(12), 1467-1469. [More Information]
  • Kao, S., van Zandwijk, N., Clarke, S., Vardy, J., Lumba, S., Tognela, A., Ng, W. (2015). Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: An evidence-based benchmark for cancer care. Asia-Pacific Journal of Clinical Oncology, 11, 85-92. [More Information]
  • Kirschner, M., Emily, P., Hoda, M., Rozsas, A., Griggs, K., Cheng, Y., Edelman, J., Kao, S., Hyland, R., Dong, Y., Vallely, M., van Zandwijk, N., Reid, G., et al (2015). Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. British Journal of Cancer, 113(6), 963-969. [More Information]
  • Williams, M., Kirschner, M., Cheng, Y., Hanh, J., Weiss, J., Amaro-Mugridge, N., Wright, C., Linton, A., Kao, S., Edelman, J., Vallely, M., Cooper, W., van Zandwijk, N., Reid, G., et al (2015). miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. Oncotarget, 6(27), 23480-23495. [More Information]
  • Kirschner, M., Cheng, Y., Armstrong, N., Lin, R., Kao, S., Linton, A., Klebe, S., McCaughan, B., van Zandwijk, N., Reid, G. (2015). MiR-Score: A novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Molecular Oncology, 9(3), 715-726. [More Information]
  • Cooper, W., Tran, T., Vilain, R., Madore, J., Selinger, C., Kohonen-Corish, M., Yip, P., Yu, B., O'Toole, S., McCaughan, B., Horvath, L., Kao, S., Boyer, M., Scolyer, R., et al (2015). PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, 89(2), 181-188. [More Information]

2014

  • Linton, A., Cheng, Y., Griggs, K., Kirschner, M., Gattani, S., Srikaran, S., Kao, S., McCaughan, B., Klebe, S., van Zandwijk, N., Reid, G. (2014). An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. British Journal of Cancer, 110(2), 510-519. [More Information]
  • Kao, S., van Zandwijk, N., Clarke, S. (2014). Comment on 'Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'. British Journal of Cancer, 111(12), 2376-2376. [More Information]
  • Linton, A., Pavlakis, N., O’Connell, R., Soeberg, M., Kao, S., Clarke, S., Vardy, J., van Zandwijk, N. (2014). Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. British Journal of Cancer, 111(9), 1860-1869. [More Information]

2013

  • Henderson, D., Reid, G., Kao, S., Van Zandwijk, N., Klebe, S. (2013). Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. Journal of Clinical Pathology, 66(10), 854-861. [More Information]
  • Henderson, D., Reid, G., Kao, S., Van Zandwijk, N., Klebe, S. (2013). Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. Journal of Clinical Pathology, 66(10), 847-853. [More Information]
  • Kao, S., Lee, K., Klebe, S., Henderson, D., McCaughan, B., Vardy, J., Clarke, S., van Zandwijk, N. (2013). Excision Repair Cross Complementation Group 1 and Thymidylate Synthase Expression in Patients With Mesothelioma. Clinical Lung Cancer, 14(2), 164-171. [More Information]
  • Kao, S., Vardy, J., Harvie, R., Chatfield, M., van Zandwijk, N., Clarke, S., Pavlakis, N. (2013). Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Supportive Care in Cancer, 21(3), 697-705. [More Information]
  • Linton, A., Kao, S., Vardy, J., Clarke, S., van Zandwijk, N., Klebe, S. (2013). Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review. Asia-Pacific Journal of Clinical Oncology, 9(3), 273-279. [More Information]
  • Honeyball, F., Boyer, M., van Zandwijk, N., Kao, S. (2013). Malignant pleural mesothelioma. Cancer Forum, 37(2), 181-185.
  • Kao, S., Clarke, S., Vardy, J., Corte, P., Clarke, C., van Zandwijk, N. (2013). Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. Internal Medicine Journal, 43(4), 402-410. [More Information]
  • Kirschner, M., Edelman, J., Kao, S., Vallely, M., van Zandwijk, N., Reid, G. (2013). The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Frontiers in Genetics, 4, 1-13. [More Information]
  • Kao, S., van Zandwijk, N., Corte, P., Clarke, C., Clarke, S., Vardy, J. (2013). Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma. Supportive Care in Cancer, 21(7), 1879-1884. [More Information]
  • Kao, S., Vardy, J., Chatfield, M., Corte, P., Pavlakis, N., Clarke, C., van Zandwijk, N., Clarke, S. (2013). Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data from Patients Seeking Compensation from the New South Wales Dust Diseases Board. Clinical Lung Cancer, 14(1), 70-77. [More Information]

2012

  • Kao, S., Armstrong, N., Condon, B., Griggs, K., McCaughan, B., Maltby, S., Wilson, A., Henderson, D., Klebe, S. (2012). Aquaporin 1 is an Independent Prognostic Factor in Pleural Malignant Mesothelioma. Cancer, 118(11), 2952-2961. [More Information]
  • Kirschner, M., Cheng, Y., Badrian, B., Kao, S., Creaney, J., Edelman, J., Armstrong, N., Vallely, M., Musk, A., Robinson, B., McCaughan, B., van Zandwijk, N., Reid, G., et al (2012). Increased Circulating miR-625-3p: A Potential Biomarker for Patients With Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 7(7), 1184-1191. [More Information]
  • Linton, A., van Zandwijk, N., Reid, G., Clarke, S., Cao, C., Kao, S. (2012). Inflammation in malignant mesothelioma - friend or foe? Annals of Cardiothoracic Surgery, 1(4), 516-522. [More Information]
  • van Zandwijk, N., Reid, G., Linton, A., Kao, S. (2012). Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools? Annals of Cardiothoracic Surgery, 1(4), 481-486. [More Information]
  • Clarey, J., Kao, S., Clarke, S., Vardy, J. (2012). The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials. Annals of Oncology, 23(5), 1229-1233. [More Information]
  • Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012). The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer, 75(2), 248-254. [More Information]

2011

  • Kirschner, M., Kao, S., Edelman, J., Armstrong, N., Vallely, M., van Zandwijk, N., Reid, G. (2011). Haemolysis during Sample Preparation Alters microRNA Content of Plasma. PloS One, 6(9), 1-9. [More Information]
  • Kao, S., Klebe, S., Henderson, D., Reid, G., Chatfield, M., Armstrong, N., Yan, T., Vardy, J., Clarke, S., van Zandwijk, N., McCaughan, B. (2011). Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy. Journal of Thoracic Oncology, 6(11), 1923-1929. [More Information]
  • Kao, S., Reid, G., van Zandwijk, N., Henderson, D., Klebe, S. (2011). Molecular biomarkers in malignant mesothelioma: state of the art. Pathology, 43(3), 201-212. [More Information]
  • Kao, S., Hovey, E., Marx, G. (2011). Second-line therapy for castrate-resistant prostate cancer: A literature review. Asia-Pacific Journal of Clinical Oncology, 7, 212-223. [More Information]
  • Kao, S., Griggs, K., Lee, K., Armstrong, N., Clarke, S., Vardy, J., van Zandwijk, N., Burn, J., McCaughan, B., Henderson, D., et al (2011). Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma. Pathology, 43(4), 313-317. [More Information]
  • Kao, S., Lee, K., Armstrong, N., Clarke, S., Vardy, J., van Zandwijk, N., Reid, G., Burn, J., McCaughan, B., Henderson, D., et al (2011). Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology, 43(2), 128-132. [More Information]

To update your profile click here. For support on your academic profile contact .